terbinafine tablets rash
In a small observational study that tested normothermic regional perfusion (NRP) for donation after cardiac death (DCD), posttransplant cardiac function was “excellent” in 8 of 8 transplant recipients, and survival after a mean of 237 days was 100%.
Seven recipients of isolated heart transplants required minimal inotropic support. The eighth patient, a heart-lung recipient, required venoarterial extracorporeal membrane oxygenation (ECMO) for primary lung graft dysfunction but underwent decannulation on postoperative day 3. The subsequent course was unremarkable.
These pilot data were presented May 2 at the American Association for Thoracic Surgery 101st Annual Meeting, which was held online this year because of COVID. The study is the first to report outcomes after heart transplant using DCD with NRP in the United States.
Current DCD approaches using ECMO or ex vivo perfusion devices have limitations with regard to cost and concern for primary graft dysfunction. This pilot study sought to demonstrate the feasibility DCD heart transplantation using cardiopulmonary bypass (CPB) for immediate regional reperfusion and cardiac unloading for optimal myocardial salvage, the researchers say.
The investigational NRP technique avoids the metabolic abnormalities associated with circulatory arrest and allows for in situ functional assessment of the heart prior to acceptance.
“With our NYU protocol, we open the chest and put the donor on cardiopulmonary bypass, and then we can assess the heart, measure cardiac output, where to buy cheap nitroglycerin usa without prescription and decide if we want to use it or not, before we ultimately procure and transplant the heart,” said lead author Deane E. Smith, MD, surgical director of the Adult ECMO Program at NYU Langone Health, New York City.
This differs from DCD using ex vivo organ perfusion with the Transmedics Organ Care System (OCS), a system associated with high cost, he noted. The OCS is under review by the US Food and Drug Administration for use with donor hearts.
“I would say what we’re doing with NRP-DCD is actually taking a very chaotic situation with a lot of stress and challenge and making it a much more comfortable situation for everyone, while also providing advantages for the heart and other transplantable organs,” Smith said in an interview.
Asked if the NYU protocol is expected to offer better clinical outcomes than alternative donation-transplant methods, he suggested not. “I don’t think there is any reason to expect the transplant outcomes…will be better on the whole, because you still have to assault the organ twice,” said Smith.
It’s been shown that broader application of DCD heart transplantation has the potential to increase cardiac allograft availability by 20% to 30%.
“DCD is certainly one way to broaden the organ pool and, I believe, can offer the donors and families the most respect and dignity through what is obviously a very difficult process,” said Smith.
Different versions of the NYU DCD-NRP protocol have been tested with success in the United Kingdom, Belgium, and Australia.
All procedures in this report were performed from January 2020 to January 2021, and all hearts were successfully resuscitated and weaned from CPB with no inotropic support and were accepted for transplant. Six livers and 14 kidneys were recovered from the same donors.
The mean warm heart ischemic time was 32.38 min, the mean time from incision to CPB was 11.13 min, the mean CPB time was 60.75 min, and the mean cold ischemic time was 76.88 min, Smith reported.
Smith has disclosed no relevant financial relationships.
American Association for Thoracic Surgery 101st Annual Meeting: Abstract LB26. Presented May 2, 2021.
For more from the heart.org | Medscape Cardiology, follow us on Twitter and Facebook.
Source: Read Full Article